The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
-
Community Cancer Institute, Clovis, California, United States, 93611
John Muir Medical Center - Concord Campus, Concord, California, United States, 94520
Compassionate Cancer Care Medical Group, Fountain Valley, California, United States, 92708
Local Institution - 0095, Fresno, California, United States, 93703
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States, 90720
Local Institution - 0258, Los Angeles, California, United States, 90095
Local Institution - 0247, Orange, California, United States, 92868
Ventura County Hematology Oncology Specialists, Oxnard, California, United States, 93030
Local Institution - 0098, Fort Collins, Colorado, United States, 80528
Hartford Hospital (HH), Hartford, Connecticut, United States, 06102
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2030-03-11